Background
Description of the technique
Mechanisms of action
Aim of study
Methods
Eligibility criteria
Information sources
Search
Study selection
Data collection process
Data items
Results
Evidence synthesis
-
Participants: patients (adults and children) with idiopathic OAB, NOUR, CPP/PBS and neurogenic bladder;
-
Intervention: Percutaneous tibial nerve stimulation (PTNS);
-
Comparison: Sham nerve stimulation; anticholinergic medications; placebo;
-
Outcome measures: cure/improvement in symptoms at the end of initial treatment program.
-
Papers with only abstract;
-
Non-English Articles;
-
Case reports;
-
Papers about PTNS non reporting clinical results.
Participants and intervention
Comparison
Outcomes
Results in overactive bladder syndrome
Randomized controlled trials on OAB
Authors | Years | Control group | PTNS | Other | RCT | Methods | Level | Results | Female n(%) | Mean age | Multicenter | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Postive | % | n | Postive | % | R | PTNS | Control group | PTNS group | Control group | ||||||||
Klingler HC | 2000 [13] | N/A | 15 | 10 | 67 | N | Urodynamic and clinical | 3 | <10 voids/day <2voids/night PadTest (g) 10 | 73 | N/A | N | ||||||
Govier FE | 2001 [14] | N/A | 47 | 71 | N | Urodynamic | 2-3 | 25% reduction in mean daytime voiding frequency | 90 | 57.4 (24–80) | Y | |||||||
van Balken MR | 2001 [15] | N/A | 37 | 22 | 59 | N | Clinical | 2-3 | Request for continued chronice treatment | 73 | 52.5 (23–74) | Y | ||||||
Vandonink V | 2003 [16] | N/A | 35 | 24 | 69 | N | Clinical | 2-3 | Continuing treatment | 71 | 57 (29–82) | Y | ||||||
Vandonink V | 2003 [17] | N/A | 60 | 34 | 57 | N | Urodynamic | 2-3 | 50% reduction | Y | ||||||||
Peters KM | 2009 [20] | Tolterodine | 44 | 35 | 80 | 42 | 23 | 55 | 0.01 | Y | Clinical | 2-3 | Improvemtn for cure in 79.5% compared to 54.8% in the tolterodine arm | 96 | 92 | 57.5 | 58.2 | Y |
Peters KM | 2010 [22] | Sham | 110 | 60 | 55 | 110 | 23 | 21 | <0.001 | Y | Clinical | 1 | Improvement in overall bladder symptoms | 78 | 80 | 62.5 | 60.2 | N |
Finazzi-Agro E | 2010 [23] | Placebo | 17 | 12 | 71 | 15 | 0 | 0 | <0.001 | Y | Clinical | 1 | 50% reduction | 100 | 100 | 44.9 | 45.5 | N |
Amarenco G | 2003 [38] | N/A | 44 | 22 | 50 | N | Clinical | 1 | 66 | 53.3 | N | |||||||
van Der pal F | 2005 [26] | N/A | 11 | 11 | 100 | N | Clinical | Improvement in overall bladder symptoms | 54.5 | 51 (33–66) | N | |||||||
Karademir K | 2005 [18] | Oxybutynin + PTNS | 21 | 13 | 62 | 22 | 18 | 82 | <0.0001 | Y | Clinical | Improvement in overall bladder symptoms | Y | |||||
de Séze M | 2011 [45] | N/A | 70 | 58 | 82.8 | N | Urodynamic and clinical | Improvement in 82.6% and 83.3% of the patients on day 30 and day 90 regarding symptoms and QoL | N | |||||||||
van Balken MR | N/A | 132 | 43 O/68 S | 32,6 O/51,5 S | N | Clinical | Improvement QoL | 61.3 | 53 (21–82) | N | ||||||||
Nuhoglu B | 2005 [19] | N/A | 35 | 19 | 54 | N | Urodynamic and clinical | Improvement Urgency and QoL | 100 | 47.3 (35–57) |
Results in non-obstructive urinary retention
Authors | Years | Control group | PNT | RCT | Methods | Level | Results | Female (%) | Mean age | Multicenter | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Positive | % | ||||||||||
van Balken MR | 2001 [15] | N/A | 12 | 7 | 58 | N | Clinical | 2-3 | Request for continued chronice treatment | 58 | 58, 8 | N |
Vandoninck V | N/A | 39 | 16 | 41 | N | Clinical | 2-3 | 50% reduction of catherterized volume | 69 | 53 (28–77) | Y | |
Vandoninck V | 2004 [24] | N/A | 39 | 16 | 41 | N | Urodynamic | 3 | 50% reduction of catherterized volume | 69 | 53 (28–77) | Y |
van der pal F | 2006 [26] | N/A | 30 | 29 | 100 | N | Bladder Diary and QoL | 2-3 | Improvement BD and QoL | 86.6 | 51 (20–72) | N |
Results in chronic pelvic pain/painful bladder syndrome
Authors | Years | Control group | PNT | Other | RCT | Methods | Level | Results | Female (%) | Mean age (range) | Multicenter | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Positive | % | n | Positive | % | PNT group | Control group | PNT group | Control group | ||||||||
van Balken MR | 2003 [27] | N/A | 33 | 14 | 42 | N | Clinical | 3 | Mean VAS for pain | 33 | 51.6 (25–79) | N | |||||
Kim SW | 2007 [28] | N/A | 15 | 9 | 60 | N | Clinical | 3 | VAS score for pain reduction >50% | 60 (41–78) | N | ||||||
Kabay S | 2009 [29] | Sham | 45 | 18 | 40 | 44 | 0 | 0 | Y | Clinical | 1 | VAS score for pain reduction >50% | 0 | 0 | 37.9 (range 24–51) | 38.5 (range 25) | N |
Zhao J | 2004 [31] | N/A | 14 | 0 | 0 | N | Clinical | 3 | VAS Scale reduction | 93 | N | ||||||
Zhao J | 2008 [31] | N/A | 18 | 8 | 44 | N | Clinical | 3 | Bladder capacity increases | 100 | 60 | N | |||||
Baykal K | 2005 [32] | N/A | 10 | 10 | 100 | N | Clinical | 3 | Wiscosin pain score | 80 | 49 (40–62) | N | |||||
Congregado Ruiz B | 2004 [33] | N/A | 51 | 51 | 100 | N | Clinical | Improvement QoL | 100 | 55 (18–74) | N | ||||||
Gokyildiz S | 2012 [34] | No treatment | 12 | 12 | 100 | 12 | 0 | 0 | Y | Clinical | Improvement QoL | 100 | 100 | / | / | N |
Results in children
Authors | Years | Control group | PNT | RCT | Methods | Level | Results | Female (%) | Mean age | Multicenter | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Positive | % | ||||||||||
Hoebeke P | 2002 [35] | N/A | 31 | 27 | 87 | Clinical and Urodynamic findings | 2-3 | Clinical and shape of the uroflowmetry curve | 48 | 11, 7 | N | |
De Gennaro M | 2004 [36] | N/A | 10 | 8 | 80 | N | 2-3 | Clinical and Urodynamic findings | 60 | 9 | N | |
De Gennaro M | 2004 [36] | N/A | 7 | 5 | 71 | N | 2-3 | Clinical and Urodynamic findings | 57 | 12 | N | |
Capitanucci ML | 2009 [37] | N/A | 14 | 12 | 86 | N | Clinical and Urodynamic findings | 2-3 | Clinical findings | NS | NS | N |
Capitanucci ML | 2009 [37] | N/A | 14 | 14 | 100 | N | 2-3 | Clinical findings | NS | NS | N |
Results in patients with neurogenic bladder
Authors | Years | Control group | PNT | RCT | Methods | Level | Results | Female (%) | Mean age | Multicenter | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Positive | % | ||||||||||
Kabay S | N/A | 32 | 15 | 47 | N | Urodynamic | 2-3 | 50% improvement cystometric capacity | 41 | 64 (44–78) | N | |
Gobbi C | 2011 [42] | N/A | 21 | 16 | 76 | N | Clinical | 2-3 | Patient perception of Bladder Cond | 76 | 46 (29–62) | N |
Kabay S | N/A | 19 | 19 | 100 | N | Urodynamic | Custometry parameters | 100 | N |